NCT02246673View on ClinicalTrials.gov

RDEA3170 and Febuxostat Combination Study in Gout Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

February 29, 2016

Conditions
Gout
Interventions
DRUG

RDEA3170 15 mg

DRUG

RDEA3170 10 mg

DRUG

RDEA3170 2.5

DRUG

RDEA3170 5 mg

DRUG

Febuxostat 40 mg

DRUG

Febuxostat 80 mg

Trial Locations (6)

33143

South Miami

66211

Overland Park

66212

Overland Park

75231

Dallas

91206

Glendale

92801

Anaheim

Sponsors
All Listed Sponsors
lead

Ardea Biosciences, Inc.

INDUSTRY